The biotech sector is witnessing a surge in gene-editing technologies, with CRISPR Therapeutics (CRSP) and Beam Therapeutics (BEAM) emerging as key players. CRISPR Therapeutics recently gained approval for its gene-editing therapy, Casgevy, which targets sickle cell disease and beta-thalassemia. This milestone positions CRISPR for significant revenue growth, bolstered by a robust pipeline, including the promising CTX310 for lowering LDL cholesterol.
In contrast, Beam Therapeutics, which focuses on base editing, has yet to commercialize a product but is making strides with its lead candidate, Risto-cel, for sickle cell disease. The company is set to submit a regulatory application soon, which could catalyze its stock performance. However, its lack of an approved product and smaller cash reserves compared to CRISPR present risks.
For investors, CRISPR Therapeutics currently appears to be the more favorable option due to its approved product, deeper pipeline, and stronger financial position, making it a compelling choice in the gene-editing space.
Source: fool.com